Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul-Aug;25(4):577-578.
doi: 10.4103/aian.aian_397_22. Epub 2022 Aug 4.

ALS Treatment- We Still Await the "Magic Cocktail"

Affiliations
Editorial

ALS Treatment- We Still Await the "Magic Cocktail"

Jasmine Shimin Koh et al. Ann Indian Acad Neurol. 2022 Jul-Aug.
No abstract available

PubMed Disclaimer

References

    1. Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:1597–604. - PubMed
    1. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448–55. - PubMed
    1. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12. - PubMed
    1. Hardiman O, van den Berg LH. Edaravone: A new treatment for ALS on the horizon. Lancet Neurol. 2017;16:490–1. - PubMed
    1. Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–17. - PMC - PubMed

Publication types